

- 1 **Supplementary Table S6.** Baseline demographics of patients with advanced solid tumors treated
- 2 with botensilimab monotherapy or botensilimab in combination with balstilimab.

Characteristics	Patients (N= 211)
Sex, n (%)	
Female	120 (57%)
Male	91 (43%)
Age (years)	
Mean ± s.d.	59 ± 12
Median	59
Range	19-83
ECOG performance status at baseline, n (%)	
0	78 (37%)
1	133 (63%)
Prior lines of therapy, n	
Median (range)	3 (1-16)
Prior anti-PD-(L)1 mAb therapy, n	63
Prior anti-CTLA-4 mAb therapy, n	7
Cancer type	
MSS Colorectal cancer (CRC)	96 (45%)
Ovarian cancer (OC)	26 (12%)
Sarcoma (SARC)	15 (7%)
Pancreatic cancer (PANC)	10 (5%)
Angiosarcoma (AS)	9 (4%)
Melanoma (MEL)	9 (4%)
Renal cell carcinoma (RCC)	5 (2%)
Ampullary of Vater carcinoma (AMPCA)	4 (2%)
Hepatocellular Carcinoma (HCC)	4 (2%)
Non-Small Cell Lung Cancer (NSCLC)	4 (2%)
Breast cancer (BRCA)	3 (1%)
Endometrial cancer (EC)	3 (1%)
Head and neck cancer (HNC)	3 (1%)
Anal cancer (ANCA)	2 (1%)
Cervical cancer (CC)	2 (1%)
Esophageal cancer (ESCA)	2 (1%)
Prostate cancer (PRCA)	2 (1%)
Thyroid carcinoma (THCA)	2 (1%)
Undetermined	2 (1%)
Adrenocortical carcinoma (ACC)	1 (0.5%)
Cholangiocarcinoma (CCA)	1 (0.5%)
Fibrolamellar carcinoma	1 (0.5%)
Gallbladder cancer	1 (0.5%)
Gastric cancer	1 (0.5%)
Mesothelioma	1 (0.5%)
Testicular cancer	1 (0.5%)
Uveal melanoma	1 (0.5%)
Treatment, n (%)	

Botensilimab monotherapy	64 (30%)
Botensilimab in combination with balstilimab	147 (70%)

3 s.d, standard deviation